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OBJECTIVES: 1) To correlate the methylation status of the O
6-methylguanine-DNA-methyltransferase (MGMT)
promoter to its gene and protein expression levels in glioblastoma and 2) to determine the most reliable method for
using MGMT to predict the response to adjuvant therapy in patients with glioblastoma.
BACKGROUND: The MGMT gene is epigenetically silenced by promoter hypermethylation in gliomas, and this
modification has emerged as a relevant predictor of therapeutic response.
METHODS: Fifty-one cases of glioblastoma were analyzed for MGMT promoter methylation by methylation-specific
PCR and pyrosequencing, gene expression by real time polymerase chain reaction, and protein expression by
immunohistochemistry.
RESULTS: MGMT promoter methylation was found in 43.1% of glioblastoma by methylation-specific PCR and 38.8%
by pyrosequencing. A low level of MGMT gene expression was correlated with positive MGMT promoter
methylation (p=0.001). However, no correlation was found between promoter methylation and MGMT protein
expression (p=0.297). The mean survival time of glioblastoma patients submitted to adjuvant therapy was
significantly higher among patients with MGMT promoter methylation (log rank=0.025 by methylation-specific PCR
and 0.004 by pyrosequencing), and methylation was an independent predictive factor that was associated with
improved prognosis by multivariate analysis.
DISCUSSION AND CONCLUSION: MGMT promoter methylation status was a more reliable predictor of susceptibility
to adjuvant therapy and prognosis of glioblastoma than were MGMT protein or gene expression levels.
Methylation-specific polymerase chain reaction and pyrosequencing methods were both sensitive methods for
determining MGMT promoter methylation status using DNA extracted from frozen tissue.
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INTRODUCTION
Gliomas are the most common primary brain tumors in
adults.
1 Glioblastomas (GBMs, World Health Organization
Grade IV) are the most frequent and malignant of these
gliomas, with tumorigenicity demonstrated even in xeno-
graft models.
2 The median survival of GBM patients
rarely exceeds 12 months.
3,4 GBMs are divided into two
subgroups: primary GBMs that emerge de novo and second-
ary GBMs that are formed from lower-grade astrocytomas.
5-7
Radiotherapy, either alone or in association with chemother-
apy, is a frequent complementary treatment to surgical
resection in GBM. Recent clinical trials have demonstrated
that the combined use of radiotherapy and alkylating agents,
particularly temozolamide, improves overall survival.
7,8
Nonetheless, only one third of GBM patients seem to benefit
from these therapies. The epigenetic silencing of the O
6-
methylguanine-DNA-methyltransferase (MGMT) gene by
promoter hypermethylation is emerging as a clinically
relevant predictor of response to treatment in glioma
patients; this predictive value may be limited to GBM.
9
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1747MGMT promoter hypermethylation can be detected in
approximately half of gliomas and is associated with longer
overall survival (OS) in patients who receive alkylating
chemotherapy in association to radiotherapy.
10,11 Alkylating
agents, most commonly chloroethylnitrosoureas (carmus-
tine [BCNU], lomustine, and fotemustine), procarbazine,
and temozolomide, induce cell death by forming crosslinks
between adjacent DNA strands through alkylation of the O
6
position of guanine. Transcriptionally active MGMT rapidly
removes the alkyl adducts, preventing the formation of
crosslinks and thereby causing resistance to alkylating
drugs.
11,12 Hypermethylation of the MGMT promoter with
consequent loss of MGMT protein expression reduces the
DNA repair activity of glioma cells, overcoming their
resistance to alkylating agents.
11
To translate this finding into a molecular diagnosis,
MGMT promoter methylation assessment must be reliable
and applicable to clinical practice. Several different meth-
odologies are available for assessing the methylation status:
1) direct study of MGMT promoter methylation or 2)
indirect assessment of its mRNA or protein expression
levels.
Various assays have been reported for determining the
MGMT promoter methylation status,
13 but the most widely
used technique is methylation-specific polymerase chain
reaction (MSP) analysis after bisulfite treatment.
14 MSP
detects CpG island methylation with high sensitivity and
specificity, particularly when high-quality DNA extracted
from frozen tissue is analyzed. Significant risks of false-
positive or false-negative results have been reported,
especially when the DNA quality and/or quantity is low
as in cases of DNA extracted from paraffin-embedded
material.
15 Although MSP is a non-quantitative method, the
methylated MGMT allele is attributed solely to neoplastic
cells
16 by bisulfite treatment; MSP is, therefore, considered a
cost-effective method for determining the MGMT promoter
methylation status in tumor samples. Pyrosequencing
(PyroS) was recently introduced as an alternative method
based on sequencing by the synthesis principle to yield
quantitative results for each individual CpG position,
17-19
including an internal control to check the efficacy of the
bisulfite treatment. Because of these characteristics, PyroS
has been reported to be the most accurate, robust, and high-
throughput method for determining MGMT methylation
status.
20,21
Alternatively, MGMT methylation status may also be
inferred indirectly from MGMT gene expression levels
determined by real-time PCR or from MGMT protein
expression level detected by immunohistochemistry (IHC),
a well-established method that is available in the majority
of histopathology laboratories.
22 Recently, the MGMT
mRNA expression level has been associated with malig-
nant glioma outcome independently of MGMT methylation
status.
23
With the availability of these various methodologies for
exploring MGMT as a predictor of outcome or response to
therapy, it is important to determine which method presents
the best combination of sensitivity, specificity, and favorable
cost-benefit ratio using the same set of samples.
Therefore, the objective of the present study was to
compare these various methods using the same set of GBM
samples and to correlate the results with the clinical end-
point of overall survival of the GBM patients.
MATERIALS AND METHODS
Tissue samples
GBM specimens were obtained during therapeutic surgical
management of patients by the neurosurgery group at
Hospital das Clı ´nicas, Department of Neurology, School of
Medicine, University of Sa ˜o Paulo, Sa ˜o Paulo, Brazil. The
specimens were examined by a neuropathologist at the
Department of Pathology of the same institution. GBM cases
were all primary and were diagnosed within three months of
theinitialappearanceofsymptoms.Thisstudywasapproved
by the local research ethics committee (#691/05), and
informed consent was obtained from each patient. Fresh
GBM samples and non-neoplastic brain tissue from temporal
lobectomy for epilepsy
23,24 were macrodissected and imme-
diately snap-frozen in liquid nitrogen upon surgical removal.
A4mm-thick cryosection of each sample was analyzed under
a light microscope after hematoxylin-eosin staining for
assessing necrosis and the presence of cellular debris and
non-neoplastic areas; following removal from the frozen
block, samples were microdissected prior to DNA and RNA
extractions. Fifty-one GBM samples from 17 female and 34
male patients with a mean age of 50.2 (SD¡14.6) years, and
19 non-neoplastic tissue samples (mean age: 37 years) were
included in the present study. Twenty-nine out of 51 GBM
patients were submitted to adjuvant radiotherapy (fractio-
nated focal irradiation in daily fractions of 2 Gy given five
days per week for six weeks for a total of 60 Gy) and/or
chemotherapy (carmustine). The degree of tumor resection
was classified as gross total resection (GTR) when more than
90% of the tumor was resected or partial resection (PR) when
less than 90% of the tumor was resected. Demographic and
clinical findings are presented in Table 1.
DNA extraction and bisulfite treatment
DNA was extracted from frozen tissue using standard
phenol/chloroform methods. To evaluate the DNA concen-
tration and purity, we measured the absorbances at 260 and
280 nm. A260/A280 ratios in the range of 1.8–2.0 were
considered satisfactory for purity standards. Bisulfite treat-
ment of up to 800 ng of DNA was performed using EpiTect
Bisulfite Kits (Qiagen, Hilden, Germany).
Total RNA extraction and cDNA synthesis
Total RNA was isolated from tissues using RNeasy Mini
Kits (Qiagen). A conventional reverse transcription reaction
was performed to yield single-stranded cDNA. The first
strand of cDNA was synthesized from 1 mg of total RNA
previously treated with 1 unit of DNase I (FPLC-pure, GE
Healthcare, Uppsala, Sweden) using random and oligo (dT)
primers, RNase inhibitor, and SuperScript III reverse
transcriptase according to the manufacturer’s recommenda-
tions (Invitrogen, Carlsbad, CA). The resulting cDNA was
subsequentlytreated with1 unit ofRNaseH (GEHealthcare),
diluted with TE buffer, and stored at -20˚C until later use.
Quantitative real time PCR
The relative expression level of MGMT was analyzed by
quantitative real-time PCR (qRT-PCR) using the SYBR
Green approach in duplicate. Quantitative data were
normalized relative to the following internal housekeeping
genes: hypoxanthine guanine phosphoribosyltransferase
(HPRT), beta-glucuronidase (GUSB), and TATA-box bind-
ing protein (TBP). The geometric mean of the three genes
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1748was used for relative expression analysis. The primer
sequences were as follows (59 to 39): MGMT F: GCTGA-
ATGCCTATTTCCACCA, MGMT R: CACAACCTTCA-
GCAGCTTCCA, HPRT F: TGAGGATTTGGAAAGGGT-
GT, HPRT R: GAGCACACAGAGGGCTACAA; GUSB F:
AAAATACGTGGTTGGAGAGCTCATT, GUSB R: CCGA-
GTGAAGATCCCCTTTTTA; TBP F: AGGATAAGAGAGC-
CACGAACCA and TBP R: CTTGCTGCCAGTCTGGAC-
TGT.
SYBR Green I amplification mixtures (12 ml) contained
3 ml of cDNA, 6 ml of 2X Power SYBR Green I Master Mix
(Applied Biosystems, Foster City, CA) and forward and
reverse primers. PCR reactions were run on an ABI Prism
7500 sequence detector (Applied Biosystems) as follows:
2 min at 50˚C, 10 min of polymerase activation at 95˚C, and
40 cycles of 15 s at 95˚C and 1 min at 60˚C. All of the primers
were synthesized by IDT (Integrated DNA Technologies,
Coralville, IA). The minimum primer concentrations neces-
sary were determined to be those concentrations that gave
the lowest threshold cycle (Ct) and maximum amplification
efficiency while minimizing non-specific amplification;
primer concentrations used were 200 nM for MGMT,
HPRT and TBP and 400 nM for GUSB. Analysis of the
DNA melting curves demonstrated a single peak for all
primers. Standard curves were analyzed for all genes to
check the efficiency of amplification of each gene.
Additionally, agarose gel electrophoresis was employed to
check the size of the PCR product amplified.
The 2
-DDCt equation was applied to calculate the relative
MGMT expression in tumor samples compared to the mean
of the non-neoplastic tissues where DCt=Ct (MGMT gene) –
Ct (geometric mean of housekeeping genes) and DDCt=DCt
(tumor) – mean DCt (non-neoplastic tissues).
25 For statistical
analysis, the MGMT expression status was scored as high-
or low-expression according to the median of the GBM
relative expression values.
Methylation-specific PCR
MSP analyzed positions 118-137 and 174-195 with the
following specific primers designed to distinguish methy-
lated (MetMGMT) from unmethylated DNA (Unmet-
MGMT)
26 (59-39): UnmetMGMT F: TTTGTGTTTTGATGT-
TTGTAGGTTTTTGT, UnmetMGMT R: AACTCCACACTC-
TTCCAAAAACAAAACA, MetMGMT F: TTTCGACGTTC-
GTAGGTTTTCGC-39 and MetMGMT R:GCACTCTTCCGA-
AAACGAAACG.
MSP using SYBR Green I was performed using PCR Core
Reagents (Applied Biosystems) with 20 ng of bisulfite-
treated DNA. Final concentrations in a volume of 10 ml
were 1X SYBR Green PCR Buffer, 1 mM of each dNTP,
200 nM of primers and 0.3 units of AmpliTaq DNA
polymerase. PCR was carried out on an ABI Prism 7500
sequence detector (Applied Biosystems) with the following
amplification program: 10 min at 95˚C followed by 40 cycles
of 95˚C for 15 s and 60˚C for 1 min. Universal unmethylated
and universal poly-methylated DNA (EpiTect Control DNA
Set, Qiagen) were included as controls in each set of
reactions in addition to a negative control sample without
DNA. Methylated and unmethylated MGMT promoter
sequences were analyzed by comparing the melting curves
of control DNAs. Additionally, the reactions were checked
by 3% agarose gel electrophoresis to verify the presence of
methylated and unmethylated MGMT promoter PCR
products of lengths 81 bp and 93 bp, respectively.
Pyrosequencing analysis
PyroS analysis was carried out for 5 CpG sites in exon 1
(positions 17 to 39, Ensembl ID: OTTHUMT00000051009) of
the MGMT promoter using a PyroMark Q24 System (Biotage,
Sweden). Primers (PyroMark Assay Database, Biotage) were
designed to hybridize with CpG-free regions to secure
methylation-independent amplification as an internal con-
trol. PCR was performed with 20 ng bisulfite-treated DNA,
Table 1 - Demographic characteristics of and clinical data
from the GBM patients analyzed in this study.
Case no. Age at dx (years)
1 Gender
2 Surgical resection
3 Treatment
4
1 71 M GTR RT&CT
2 65 F GTR SR
3 47 F GTR RT
4 78 F GTR RT
5 45 M PR RT&CT
6 54 F PR RT
7 68 M PR SR
8 67 M GTR RT&CT
9 57 F PR SR
10 17 F PR CT
11 59 F PR RT
12 41 F PR RT&CT
13 55 M GTR SR
14 42 M PR RT
15 56 F GTR SR
16 45 M GTR RT&CT
17 62 F PR SR
18 52 M PR SR
19 51 M GTR SR
20 35 M PR SR
21 39 M PR RT&CT
22 60 M PR SR
23 46 M PR RT&CT
24 35 M PR SR
25 49 M PR SR
26 52 F GTR RT&CT
27 57 M PR RT
28 16 M PR SR
29 55 M GTR RT
30 40 M GTR SR
31 26 M GTR RT
32 40 M PR RT&CT
33 68 F PR SR
34 28 F PR SR
35 38 F PR RT
36 32 M GTR RT&CT
37 55 M PR RT&CT
38 54 M PR RT&CT
39 61 F PR SR
40 52 M PR RT&CT
41 63 M PR SR
42 52 M PR SR
43 76 M PR SR
44 39 M PR RT&CT
45 68 F PR RT
46 58 F PR RT
47 26 M PR SR
48 69 M PR RT
49 31 M PR SR
50 47 M PR RT&CT
51 63 M PR RT&CT
1Age at diagnosis was calculated from date of birth to date of surgery.
2M, male; F, female.
3GTR, gross total resection; PR, partial resection.
4SR=surgical resection; RT=radiotherapy; CT=chemotherapy; RT &
CT=radiotherapy and chemotherapy.
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1749200 mM of each primer, 12.5 ml PyroMark 2X PCR master
mix, 2.5 ml CoralLoad Concentrate 10X (provided in the
PyroMark PCR Master Mix, Qiagen), and HotStar Taq
polymerase. PCR conditions were 95˚C for 15 min; 45 cycles
of 94˚C for 30 s, 53˚C for 30 s, and 72˚C for 30 s; and 72˚Cf o r
10 min. PCR products of 104 bp were checked by 2% agarose
gel electrophoresis. Subsequent quantification of the methy-
lation density of five CpG sites was performed using the
PyroMark Q24 software. Subsets of GBM cases were
reanalyzed with repeated PCR and PyroS reactions to test
the reproducibility of the findings. Two subgroups were
defined for statistical analysis according to an average of
CpG residue methylation: 1) an unmethylated group, for
which the mean range was ,10%, and 2) a methylated
group, including those samples with an intermediate status
(mean range of 10-26%) or a methylated status (mean range
$27%).
Immunohistochemistry
Four-micrometer sections were prepared from paraffin-
embedded tumor blocks for IHC analysis. Briefly, antigen
retrieval was performed in 10 mM citrate buffer (pH 6.0) at
122˚C for 3 min using an electric pressure cooker (BioCare
Medical, Walnut Creek, CA). Specimens were subsequently
blocked and incubated further with a mouse monoclonal
antibody raised against human MGMT (Clone MT 3.1,
Neomarkers Inc., Fremont, CA) at a final dilution of 1:500 at
4˚C overnight. Antigen-antibody reactions were revealed
using a commercial kit (Novolink, Novocastra, Newcastle,
UK) at room temperature; diaminobenzidine was used to
detect the signal, and Harris hematoxylin was used as a
nuclear stain. A positive control tissue (colon adenocarci-
noma) was used to confirm the consistency of the
immunostaining, and all samples were stained in a single
batch.
Figure 1 - Comparison of the MGMT promoter methylation status of GBM cases analyzed using MSP and PyroS. Five CpG sites were
analyzed using PyroS, and 8 CpG sites were analyzed using MSP. For PyroS, the MGMT methylation status was scored according to the
average percentage of specifically methylated CpG sites as unmethylated (U) when ,10% CpG sites were methylated, intermediate (I)
when 10 to 26% CpG sites were methylated, or methylated (M) when $27% of CpG sites were methylated. For MSP, the MGMT
methylation status was scored as methylated (M) or unmethylated (U) according to the presence or absence of the specific PCR
amplification.
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1750MGMT expression was assessed and scored in tumor cells
by two independent observers who were blinded to tumor
methylation status and clinical data according to the
following semi-quantitative classification method based on
percent of nuclei that were positive: 0 (no staining), 1 (10–
25%), 2 (26–50%), or 3 (.50%). Endothelial staining was
Figure 2 - Correlation between relative gene expression level of MGMT and promoter methylation status determined using MSP (A) and
PyroS (B). MGMT expression levels in the GBM samples were determined relative to non-neoplastic tissues. The horizontal bars show
the median values for the relative expression of MGMT in each group. The Mann-Whitney test was used to evaluate the differences in
the relative expression level between the methylated and unmethylated groups.
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1751used as an internal control for MGMT immunostaining. In
accordance with previous reports, MGMT staining was
considered positive when uniform MGMT staining was
detected in the cell nuclei.
27 Reactivity that was restricted to
the cytosol and granular nuclear reactivity were considered
negative.
27 Endothelial cells and perivascular lymphocytes
were excluded from positive cell counts. For statistical
analysis, scores of 0 were defined as the absence of protein
expression, and scores of 1 to 3 were defined as positive for
protein expression. The x
2 test was used to evaluate the
association between the MGMT promoter methylation
status (negative versus positive) and protein expression
levels (absence versus positive).
Statistical analysis
The x
2 test was used to evaluate the associations between
the MGMT promoter methylation status (negative versus
positive) and the gene and protein expression levels. The
Mann-Whitney test was used to analyze the differences in the
relative expression levels between the two groups (methy-
lated versus unmethylated) as determined by MSP and PyroS.
Overall survival (OS) was calculated from the day of surgery
totheday ofdeathand wasexpressed in months.TheKaplan-
Meier survival curve was analyzed using the log rank (Mantel
Cox)testandmultivariateanalysisusingtheCoxproportional
hazards model. The logistic regression model included the
following parameters: age at diagnosis, gender (female versus
male), degree of tumor surgical resection (gross total
resection, GTR versus partial resection, PR) and MGMT
promoter methylation status (methylated versus unmethy-
lated) assessed using PyroS and MSP. Calculations were
performed using STATA version 7 (STATA Corp., College
Station, TX) and SPSS 15.0 (SPSS, Chicago, IL). Also, p-values
lower than 0.05 were considered statistically significant.
RESULTS
MGMT promoter methylation status
MGMT promoter methylation was detected in 43.1% (22
out of 51) of the GBM samples by MSP and in 38.8% (4
intermediate and 15 methylated out of 49) of the samples by
PyroS. Two of the 51 GBM cases were excluded from the
PyroS method analysis, due to unsuccessful PCR amplifica-
tion. MGMT methylation status was determined with 91%
concordance for the two methods. Although PyroS revealed
two cases of intermediate methylation that went undetected
by MSP, the former method failed to detect three methy-
lated cases that were detected by MSP. These three cases
were methylated at a CpG site revealed by the primer set for
PyroS, as shown in Figure 1.
MGMT gene expression
MGMT gene expression was determined by qRT-PCR.
The median expression levels in GBM did not differ
significantly from those of non-neoplastic brain tissues
(1.16 versus 0.91, respectively, p=0.597). However, when
MGMT expression levels were analyzed in the two
subgroups (methylated versus unmethylated), a significant
difference was observed with higher expression levels
found in the methylated subgroup using either MSP
(p,0.0001, Figure 2A) or PyroS (p,0.001, Figure 2B).
Furthermore, as revealed by qualitative analysis, the
correlation between the methylation status of the MGMT
promoter and the relative MGMT expression level (either
positive promoter methylation and low expression or
negative promoter methylation and high expression) was
statistically significant (p=0.001, 72.5% concordance for
MSP; p=0.002, 71.4% concordance for PyroS).
MGMT protein expression
Positive expression of MGMT protein in tumor cell nuclei (as
analyzed by IHC) was observed in 38 out of 51 (74.5%) GBM
cases; there were 33 cases with a positivity score of 1+positivity
and only five cases with a score of 2+ (Figure 3). Among the 38
positive cases, 47.4% (by MSP) and 57.1% (by PyroS) were
positive for MGMT promoter methylation. In contrast, only
31% (4 out of 13) of cases showing no staining on IHC were
positive for MGMT promoter methylation. Consequently, no
significant correlation between MGMT protein expression and
MGMT promoter methylation status was found. The con-
cordances between IHC and either MSP or PyroS were only
47% and 57.1%, respectively. Other comparative analyses of the
IHC protein expression scores and methylation status (con-
sidering 0 and 1+ staining as negative protein expression or 2+
as positive protein expression) demonstrated a similarly low
concordance between the two methods.
An overview of the results of the present study is shown in
Figure 3 as a heatmap and includes MGMT promoter
methylation status and gene and protein expression findings.
Influence of MGMT promoter methylation status
and gene and protein expression on prognosis
The mean OS of the GBM cases was 13¡14.0 months.
MGMT gene and protein expression levels were not
correlated with OS (p.0.05, data not shown). Similarly,
MGMT promoter methylation status (as determined by
MSP) did not appear to affect OS, which was 17.2 months
for the methylated group and 9.5 months for the unmethy-
lated group (p=0.297). However, when only the 29 GBM
cases submitted to adjuvant chemotherapy with radio-
therapy and/or chemotherapy were considered, the mean
OS times differed significantly between the two groups (27.4
months for the methylated group and 12 months for the
unmethylated group, p=0.025), indicating a stronger ther-
apeutic response in the methylated group (Figure 4A). The
mean OS was also significantly longer in the methylated
group (31.7 months) than in the unmethylated group (11.8
months) (p=0.004) determined by PyroS (Figure 4B). A
Figure 3 - Heatmap of the MGMT analyses showing methylation status as assessed by MSP and PyroS, quantitative real-time PCR (qRT-
PCR) for MGMT relative gene expression and immunohistochemistry (IHC) for MGMT protein expression. MSP and PyroS: green,
methylated; yellow, intermediate; red, unmethylated; and white, not determined. qRT-PCR: green, low expression; red, high
expression. IHC: green, negative staining; red, positive staining.
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1752multivariate Cox regression model (which considered age at
diagnosis, gender, degree of tumor surgical resection, and
MGMT promoter methylation status) showed that only
MGMT promoter methylation status assessed either by
MSP or PyroS was an independent prognostic factor (hazard
ratio=0.342, p=0.023 and hazard ratio=0.218, p=0.005,
respectively) as indicated in Table 2. Comparison of the
methylation levels of the five CpG sites individually (above
versus below the median level) yielded similar results
(p=0.004 for CpG1, CpG2 and CpG5 and p=0.002 for
CpG3 and CpG4, data not shown).
DISCUSSION
In the present study, MGMT promoter methylation as
determined by two distinct methods had a significant
impact on overall survival among patients treated with
radiotherapy and/or chemotherapy as reported by other
researchers in clinical trials and meta-analyses.
10,11,28-31 The
frequency of MGMT promoter methylation in our study was
in agreement with previously described results in primary
GBM, which range from 36-45%.
10,15,32-33 Using one set of
GBM samples, we were able to predict the therapeutic
Figure 4 - Kaplan-Meier curves showing the overall survival of GBM patients submitted to adjuvant therapy (radiotherapy and/or
chemotherapy) and grouped according to MGMT promoter methylation status as determined by MSP (A) and PyroS (B). The difference
in overall survival times between the methylated and unmethylated groups was statistically significant for both methods (log-rank test:
p=0.025 for MSP and p=0.004 for PyroS).
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1753response using either a qualitative (MSP) or a quantitative
(PyroS) method to assess the methylation status of the
MGMT promoter. A high level of concordance (91%)
between the two methods was observed. MSP provided
slightly higher sensitivity while covering more CpG sites in
the analysis than PyroS (8 versus 5 CpG sites). However,
PyroS detected an intermediate methylation state that was
not revealed by MSP. Additionally, the analysis of the five
CpG sites together or separately predicted response to
therapy in our set of GBM cases. In fact, the status of only a
few CpG sites may be an adequate predictor of OS if high
quality DNA is extracted from frozen tissue, which
improves the sensitivity of methylation assessment,
32 and
adequate internal controls to detect incomplete bisulfite
conversion and false priming are used. The accurate and
robust results for MGMT promoter methylation status
achieved by assessment of only four CpG sites
20 located
immediately downstream of those investigated in the
present study corroborate this notion. Moreover, the
methylation status of CpG4 alone has also proved to be a
good predictor of OS.
31
Another important issue in bringing a result from the
laboratory bench to bedside practice is the cost-benefit ratio.
To this end, we analyzed the reliability of two low cost
methods for indirectly assessing MGMT methylation status:
1) MGMT gene expression level by straightforward qRT-
PCR method and 2) MGMT protein expression level by
IHC, a routine method widely available in histopathology
laboratories. We compared the results of both methodolo-
gies to the MGMT methylation status. The positive correla-
tion observed between the presence of MGMT promoter
methylation and low expression of this gene may be
explained by the use of the same microdissected frozen
tumor fragment for DNA and RNA extractions and also by
normalization of qRT-PCR results using three housekeeping
genes instead of one.
34,35 Nevertheless, the concordance
between the MGMT gene expression level and methylation
status determined by MSP was 72.5%, and this discrepancy
may be due to the difficulty of determining the cut-off level
for dividing the cases into groups with high or low MGMT
gene expression. In the present study, the cut-off was
arbitrarily determined as the median average value of the
gene expression level in all GBM cases (1.16), although other
criteria may also be acceptable. Recently, MGMT mRNA
expression has been shown to play a direct role in mediating
tumor sensitivity to alkylating agents independently of
MGMT promoter methylation.
23 Some methodological
differences, such as the housekeeping genes used in that
study compared to the present one, may explain the
discrepancy, as may the fact that some CpG sites better
reflect the MGMT gene expression level than others.
36
Therefore, the reliability of assessing MGMT methylation
status indirectly by MGMT qRT-PCR remains an open
question.
No significant correlation between MGMT protein expres-
sion (as determined by IHC) and methylation status was
found, and concordances of only 47.4% (MSP) and 57.1%
(PyroS) were observed. The presence of sampling bias in the
methods with the smaller frozen fragments needed for the
methylation study compared to the typically larger paraffin-
embedded sections used for IHC, and the inclusion of
endothelial cells, tumor-infiltrating lymphocytes or a variety
of normal resident cells preserved within tumors may
represent confounding factors for evaluation by IHC.
21,37,38
Heterogeneity of the cell subpopulation comprising GBM
tumors is an additional factor that could explain the
discrepancy between the results of these two methods. The
concomitant detection of both methylated and unmethylated
status in the majority of GBM specimens analyzed in the
present study corroborates the existence of this heterogene-
ity, as described previously.
39,40 Furthermore, other factors,
such as the p53 status, may also influence the final level of
MGMT protein expression. Tumors with normal p53 status
are more likely to have low or absent MGMT expression
independently of the MGMT promoter methylation status.
41
Therefore, although IHC is a more accessible method than
MSP or PyroS, MGMT protein expression is not a reliable
method for inferring MGMT methylation status.
CONCLUSION
In summary, in one set of samples, the MGMT promoter
methylation status but not the MGMT mRNA or protein
expression levels was confirmed as a factor predicting the
response to adjuvant therapy in GBM patients.
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